Ibrutinib in previously treated Waldenström's macroglobulinemia.

doi:10.1056/NEJMoa1501548

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ibrutinib in previously treated Waldenström's macroglobulinemia.

The New England journal of medicine - 9 Apr 2015

Treon Steven P, Tripsas Christina K, Meid Kirsten, Warren Diane, Varma Gaurav, Green Rebecca, Argyropoulos Kimon V, Yang Guang, Cao Yang, Xu Lian, Patterson Christopher J, Rodig Scott, Zehnder James L, Aster Jon C, Harris Nancy Lee, Kanan Sandra, Ghobrial Irene, Castillo Jorge J, Laubach Jacob P, Hunter Zachary R, Salman Zeena, Li Jianling, Cheng Mei, Clow Fong, Graef Thorsten, Palomba M Lia, Advani Ranjana H

Abstract excerpt

BACKGROUND: MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenström's macroglobulinemia. MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib. CXCR4(WHIM) mutations confer in vitro resistance to ibrutinib. METHODS: We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemoglobins

Share to Immunoglobulin M

Share to Myeloid Differentiation Factor 88

Share to Piperidines

Share to Pyrazoles

Share to Receptors, CXCR4

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed

Identifiers

PMID: 25853747
DOI: 10.1056/NEJMoa1501548

Genes

CXCR4
MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ibrutinib in previously treated Waldenström's macroglobulinemia.PMID 25853747Read ↗

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.Semantic proximity Read ↗

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.Semantic proximity Read ↗

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.Semantic proximity Read ↗

Emerging drugs for the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.Semantic proximity Read ↗

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.Semantic proximity Read ↗

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Semantic proximity Read ↗

Novel Approaches in Waldenström Macroglobulinemia.Semantic proximity Read ↗

How to Sequence Therapies in Waldenström Macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.